TreatmentTrends: Dry/Wet Age-Related Macular Degeneration 2015 (US) is the fifth annual syndicated report series that offers a snapshot of dry and wet age-related macular degeneration (AMD) market dynamics and the competitive landscape through comprehensive primary research with retinal specialists and general ophthalmologists who personally administer anti-vascular endothelial growth factor (VEGF) injections. The report provides valuable insight into the current and anticipated treatment of patients with dry and wet AMD, with a particular focus on the administration of intravitreal anti-VEGF agents (i.e., off-label Avastin, Eylea, Lucentis). We also assess surveyed physicians’ perceptions of these wet AMD products—e.g., their advantages and disadvantages, ideal patient types, barriers to growth—and current detailing and messaging efforts for approved wet AMD brands. Respondents are asked about their awareness of products in development for dry or wet AMD and anticipated integration of these products in the treatment algorithm, as well as the potential for biosimilars in the wet AMD market.
Questions Answered in This Report:
- While no approved pharmacotherapy agents are available for the treatment of any forms of dry AMD, off-label Avastin continues to dominate the wet AMD market owing to its low cost and easy access. How are patients with wet AMD and different forms of dry AMD (i.e., early, intermediate, geographic atrophy) being managed and treated? How has the treatment algorithm (e.g., line of therapy, typical patient type) changed compared with the previous four years? Where do retinal specialists and general ophthalmologists differ in their management of AMD patients? Is treatment anticipated to change over the next six months? What factors are driving these anticipated changes?
- Overall satisfaction with Eylea has increased significantly compared with the first year post-launch driven by significantly higher performance ratings on key influencers of brand choice. What product attributes are most important to physicians when they select a specific wet AMD therapy? How do physicians believe the current anti-VEGF agents perform on each attribute and against each other? How has brand performance changed over the past five years? What messaging efforts are Regeneron and Genentech employing to differentiate their product? How have the DRCR.net Protocol T Study results in diabetic macular edema impacted physicians’ willingness to prescribe the products for wet AMD?
- Multiple therapies are in mid- to late-stage development for the treatment of dry AMD (e.g., lampalizumab, emixustat hydrochloride) and wet AMD (e.g., Fovista, abicipar pegol, squalamine, and RTH-258). How familiar are physicians with these products? Which products do they perceive as offering the most value and what characteristics drive the value? Will adjunctive therapies play a role in first-line therapy or be reserved for treatment-resistant patients? How will biosimilars be incorporated into the treatment algorithm? What current products are most at risk by the potential future launch of pipeline products and biosimilars?
Markets covered: United States.
Primary research: 99 retinal specialists and general ophthalmologists.
Indication coverage: dry AMD, wet AMD.
Emerging therapies: Phase II: 2 drugs; Phase III: 4 drugs.